BiomX Posts Q2 Loss With 14% Cost Drop
BiomX (NYSEMKT:PHGE), a clinical-stage biotechnology firm specializing in bacteriophage therapies to address antibiotic-resistant bacterial infections, released its second-quarter fiscal 2025 results on August 13, 2025. The company reported no revenue during the period and a GAAP earnings per share loss of $(0.26), which matched estimates. Operating expenses, including research and development costs, declined from last year. Despite positive clinical milestones in its lead programs, the continued absence of revenue highlights the company’s ongoing reliance on external financing. Overall, the quarter showed tangible R&D progress and cautious financial management, but no change yet to the underlying cash burn profile or overall early-stage status.
Source: BiomX. Note: Analysts' consensus estimates provided by FactSet.
BiomX develops bacteriophage-based therapies, which use viruses that specifically target and kill harmful bacteria, as a new way to treat infections that resist antibiotics. Its platform technology, BOLT, enables agile and efficient development of optimized phage cocktails. This approach positions BiomX to address difficult medical problems where existing antibiotics no longer work.
Source Fool.com
